2023-06-07 19:28:16
ABU DHABI, 7th June / WAM / Hayat Biotech, a pioneer in the field of biotechnology in the UAE, hosted a panel discussion that discussed the future of the health care system in the United Arab Emirates, and the global role of the Emirate of Abu Dhabi in this sector, with the participation of health care experts and representatives of the Department of Health – Abu Dhabi. .
In line with the goal of the Department of Health – Abu Dhabi to enhance Abu Dhabi’s position as a global center for research and innovation in life sciences, the discussion session was held under the title: “A Revolution in Life Sciences from Abu Dhabi” within the framework of the cooperation signed between the Department of Health and Hayat Biotech in January 2023, to enhance the exchange of knowledge and experiences. and exploring priorities and key areas for activation and collaboration.
The discussion session began with a welcome speech by Nasser Al-Yamahi, Executive Vice President of Hayat Biotech. The session was moderated by Mustafa Al-Rawi, Acting General Manager of the “CNN Economics” media platform, and a group of health care experts participated in it, including Dr. Dirk Colmer, founding partner. for the Fraunhofer Project Center, Dr. Nawal Al-Kaabi, Senior Advisor at Hyatt Biotech, Dr. Dirk Reicher, Director of Innovation for the Health Sector at the Department of Health – Abu Dhabi, Yunli Zhao, Vice President of Hyatt Biotech Productions, and Dr. Mira Mousa, Deputy Director of the Discovery Biomedical Sciences Program Khalifa University.
Participants presented their opinions and views on the role of clinical trials, the importance of research and development, and the advanced manufacturing capabilities of the United Arab Emirates, which will enhance Abu Dhabi’s role in leading the life sciences sector in the Middle East and North Africa region and at the global level.
Hyatt Biotech’s advanced biotechnology facilities in Abu Dhabi and Belgrade, Serbia, with a total annual production capacity of 230 million packages, play a critical role in achieving the company’s global ambitions.
By attracting international companies to transfer their production to these facilities, Hayat Biotech has succeeded in forming successful partnerships and establishing itself as a preferred destination for bioindustrial companies seeking to establish production facilities in the UAE to serve the local and regional markets.
After the discussion, representatives of the Fraunhofer Association and Hyatt Biotech engaged in additional conversations to explore the possibility of collaborating on clinical trials, diagnostic products, and vaccines.
Due to its strategic geographical location, Abu Dhabi constitutes a safe and effective gateway for global distribution, especially the healthcare sector.. The concerned authorities in the UAE have taken proactive measures by implementing a variety of programs and initiatives, which enhances the attractive environment for international companies to establish a presence in the region.
By benefiting from developments in the field of health care, the UAE has established itself as a prominent hub for logistics, transportation and distribution of medicines, and plays an active role in promoting global health.
Nasser Al Yamahi, Executive Vice President of Hayat Biotech, said: “We are committed to supporting the Department of Health’s ambitious vision of making Abu Dhabi a global center for biotechnology and life sciences. We focus our efforts on cooperation with international pharmaceutical companies, to facilitate the transfer of manufacturing of the company’s products to Abu Dhabi, and to help them achieve their goals.. We always strive to achieve a positive reflection in the sector at the global level, and to promote biotechnology and life sciences for generations coming».
Dr. Nawal Al-Kaabi, Senior Advisor at Hyatt Biotech, said: “At Hyatt Biotech, we seek to protect current and future generations by providing medicine and vaccines easily, and supporting the advancement of research and development.. Conducting clinical trials in Abu Dhabi provides access to diverse groups of patients that may not otherwise be available. They are available in other regions, and this diversity is crucial for testing the efficacy and safety of drugs on different ethnic groups and people with different health conditions, which provides more accurate results and better treatments.”
She added, “Our cooperation with the Department of Health – Abu Dhabi has been successful, and we seek to strengthen it and expand the scope of cooperation, with the aim of providing access to new and innovative treatments, both locally and globally.” These trials, including eight important clinical trials it conducted in the UAE, and “Forhumane” is one of the largest clinical trials for inactivated vaccines in the world..Hayat Biotech is working on developing innovative biopharmaceutical products that meet medical needs and improve current treatments. “He explained that thanks to the company’s efforts to develop Medical sciences, Hayat Biotech has become a trusted partner for biopharmaceutical companies looking to conduct clinical trials and launch new products in the market.Hayat Biotech affirms its continuous commitment to the development of the healthcare sector through innovative solutions and strategic partnerships with local and global stakeholders. Abu Dhabi Establishing its position as a leading center for research, development and production of biopharmaceuticals, Hayat Biotech plays an important role in driving this progress forward .. The company enjoys a leading position capable of making a significant positive impact in the global life sciences sector, thanks to its advanced facilities and its team of highly qualified experts.
1686168404
#Emirates #News #Agency #participation #representatives #Department #Health #Hayat #Biotech #hosts #panel #discussion #entitled #Revolution #Life #Sciences #Abu #Dhabi